Related Experiment Video
Updated: Jan 8, 2026
Non-Destructive Evaluation of Regional Cell Density Within Tumor Aggregates Following Drug Treatment
Published on: June 21, 2022
Patritumab deruxtecan in breast cancer treatment: a drug evaluation
Adina Sabau1, Jessica Paparo1,2, Rasha Cheikh-Hussin3
1Department of Medical Oncology, Gustave Roussy, Villejuif, France.
Abstract:
Breast cancer is a complex disease due to its heterogeneity. While there have been impressive advancements in the treatment of the different breast cancer subtypes, challenges persist when the tumor develops acquired treatment resistance and finally progresses on a given therapy. Since human epidermal growth factor receptor 3 (HER3) plays a key role in developing resistance to several anticancer therapies, many efforts have been performed over the last decades to effectively target HER3. However, most of these attempts have been unsuccessful due to their limited efficacy or severe toxicity. Numerous antibody-drug conjugates (ADCs) targeting HER3 are now being explored. Patritumab deruxtecan (U3-1402; HER3-DXd), the most advanced ADC targeting HER3 in clinical development, has demonstrated significant antitumor activity and a manageable safety profile in patients with breast cancer. This efficacy has been observed across diverse tumor subtypes and varying levels of HER3 expression. In this review, we will analyze the results of clinical trials investigating HER3-DXd in breast cancer and explore its potential role in future clinical applications and treatment algorithms.
Insights
Patritumab deruxtecan (HER3-DXd) shows significant antitumor activity and a manageable safety profile in breast cancer patients. This advanced antibody-drug conjugate offers a promising new therapeutic option for various breast cancer subtypes.
Area of Science:
- Oncology
- Pharmacology
- Translational Research
Background:
- Breast cancer heterogeneity poses treatment challenges, particularly acquired resistance.
- Human epidermal growth factor receptor 3 (HER3) is implicated in resistance to multiple anticancer therapies.
- Previous attempts to target HER3 have faced limitations in efficacy and safety.
Purpose of the Study:
- To review clinical trial results of patritumab deruxtecan (HER3-DXd) in breast cancer.
- To explore the potential role of HER3-DXd in future breast cancer treatment strategies.
Main Methods:
- Analysis of clinical trial data for patritumab deruxtecan (HER3-DXd).
- Evaluation of efficacy across diverse breast cancer subtypes and HER3 expression levels.
- Assessment of safety profile and patient outcomes.
Main Results:
- Patritumab deruxtecan (HER3-DXd) demonstrated significant antitumor activity.
- The antibody-drug conjugate exhibited a manageable safety profile in breast cancer patients.
- Efficacy was consistent across various tumor subtypes and HER3 expression levels.
Conclusions:
- Patritumab deruxtecan (HER3-DXd) represents a promising advancement in HER3-targeted therapy for breast cancer.
- This antibody-drug conjugate may play a crucial role in future breast cancer treatment algorithms.
- Further investigation into HER3-DXd's clinical applications is warranted.
